Table 3.
Summary of co-delivery of small molecule drug and siRNA mediated by polymer-based nanomaterials for cancer therapy.
| Delivery System | Small Molecule Drug | siRNA Target |
Type of Cancer | Cell Line | Testing Stage | Ref. |
|---|---|---|---|---|---|---|
| Chitosan based pH-responsive polymeric prodrug vector (GA-CS-PEI-HBA-DOX) where GA-CS-PEI-HBA-DOX is prodrug chitosan-polyethylenimine-4-hydrazino-benzoic acid doxorubicin |
Doxorubicin | BCL2 | Liver cancer | HUVEC, HepG2 |
In vitro
In vivo |
[44] |
| Amphiphilic block copolymer of monomethoxylpoly(ethylene glycol), poly(l-lysine), and poly(aspartyl(Benzylamine-co-(Diisopropylamino)ethylamine)) mPEG-PLLys-PLAsp(BzA-co-DIP), abbreviated as PELABD micelles | Doxorubicin | siRNA | Ovarian cancer | SKOV3 | In vitro | [46] |
| Triblock copolymer nanocarrier of PAH-b-PDMAPMA-b-PAH where PAH-b-PDMAPMA-b-PAH is poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH) |
Doxorubicin | BCL2 | Breast cancer | MCF-7 | In vitro | [56] |
| PEG-PCL-PEI triblock copolymer nanomicelle functionalized with folic acid | Doxorubicin | (P-gp) siRNA | Breast cancer | MCF-7/ADR | In vitro | [57] |
| Poly(ε-caprolactone), polyethylenimine and polyethylene glycol (PCL-PEI-PEG) copolymers | 4-(N)-stearoyl gemcitabine | RELA | Pancreatic cancer and breast cancer | AsPC-1, MCF-7 | In vitro | [58] |
| Lipid-polymer hybrid nanoparticles where cationic ε-polylysine co-polymer nanoparticles (ENPs) are coated with PEGylated lipid bilayer resulted formation of LENPs, with reversed surface charge |
Gemcitabine | HIF1A | Pancreatic cancer | Panc-1 |
In vitro
In vivo |
[59] |
| pH/redox dual-sensitive polymeric materials (cPCPL) where cPCPL is poly(ethylene glycol))x-(chitosan-polymine)y-(lipoic acid)z grafted with cRGDyC-PEG-NHS, cRGDyC is a kind of peptide, PEG is poly(ethylene glycol) and NHS is hydroxysuccinimide. |
Etoposide | EZH2 | Orthotopic non-small-cell lung tumour | luc-A549 |
In vitro
In vivo |
[60] |
| Self-assembled polyjuglanin nanoparticles (PJAD-PEG) where PJAD-PEG is poly(juglanin (Jug) dithiodipropionic acid (DA))-b-poly(ethylene glycol) (PEG) |
Doxorubicin | KRAS | Lung cancer | A549, H69 |
In vitro
In vivo |
[61] |
| Cationic polyethylenimine-block-polylactic acid (PEI-PLA) | Paclitaxel | BIRC5 | Lung Adenocarcinoma | 4T1, A549 |
In vitro
In vivo |
[62] |
| Lactic-co-glycolic acid (PLGA) nanoparticles | Paclitaxel | SPDYE7P | Cervical cancer | HeLa |
In vitro
In vivo |
[63] |
| FeCo-polyethylenimine (FeCo-PEI) nanoparticles and polylactic acid-polyethylene glycol (PLA-PEG) | Paclitaxel | FAM group | Breast cancer | MCF-7, BT-474 | In vitro | [64] |
| Hypoxia-sensitive PEG-azobenzene-PEI-DOPE (PAPD) nanoparticles | Doxorubicin | ABCB1 | Ovarian cancer and breast cancer | A2780 ADR, MCF7 ADR | In vitro | [65] |
| Chondroitin sulfate (CS)-coated β-cyclodextrin polyethylenemine polymer | Paclitaxel | MCAM | Breast Cancer | MDA-MB-231, MCF-7 | In vitro | [66] |
| Targeted multifunctional polymeric micelle (TMPM) where TMPM is made up of triblock copolymer poly(ε-caprolactone)-polyethyleneglycol-poly(L-histidine) (PCL-PEGPHIS) |
Paclitaxel | VEGF group | Breast Cancer | HUVECs, MCF-7 | In vitro | [67] |
Note: BCL2, BCL2 apoptosis regulator; HIF1A, hypoxia inducible factor 1 subunit alpha; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; KRAS, KRAS proto-oncogene, GTPase; BIRC5, baculoviral IAP repeat containing 5; SPDYE7P, speedy/RINGO cell cycle regulator family member E7 pseudogene; FAM group, long non-coding family with sequence group; ABCB1, ATP binding cassette subfamily B member 1; MCAM, melanoma cell adhesion molecule; VEGF group, vascular endothelial growth factor group; RELA, RELA proto-oncogene, NF-kB subunit.